Panelists Shed Light on Manufacturing Facilities for Novel Therapeutics

The Novel Therapeutics panel discussion on December 6th was a great success, with nearly 80 attendees and a strong panel of experts consisting of Stacy Price of Ziopharm, Bankim Patel of Moderna, John Dougherty of DPS, consultant Lance Weed and moderator Jeffrey Kent of DPS.

The design of manufacturing facilities for novel therapeutics requires careful planning and consideration of many factors such as throughput, biosafety level, product segregation as well as contamination control, regulatory environment, time to market, and tech transfer challenges. This complex mix of elements requires a project team that can move quickly and effectively to de-risk the investment and meet market demand.

The panelists had recently delivered or were in the midst of developing facilities and programs for scale up and manufacturing of these novel therapies. Their real-world expertise resonated with the audience and led to a lively, interactive panel discussion and a robust Q&A session.

A huge thank you to Novartis for welcoming the Boston Area Chapter to their incredible facility. And special thanks to our distinguished panelists and moderator, Meeting Manager Gerry Archambault of Process Water, and to the Chapter’s admin staff for all their support!